LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Parker brings over 25 years of experience in the healthcare and biotech sectors, where he has spearheaded successful product launches and expansion strategies, particularly in the field of rare diseases.
In his new role, Parker will lead the global commercial strategy for Savara’s molgramostim inhalation solution, a treatment for autoimmune Pulmonary Alveolar Proteinosis (aPAP). This appointment comes as Savara gears up for a pivotal period, with the anticipated approval and launch of molgramostim, which if approved, would be the first treatment for aPAP available in both the U.S. and Europe.
Matt Pauls, Chair and CEO of Savara, expressed enthusiasm about Parker joining the team, stating, “I am happy to welcome Braden to Savara, particularly as we approach a transformational milestone with the potential approval and launch of molgramostim. Braden is an accomplished leader with a proven track record of building commercial teams, leading successful rare disease product launches and accelerating growth for companies as they transition to the commercial stage.”
Parker’s career includes roles at Orchard Therapeutics, where he oversaw the global launch of Libmeldy for metachromatic leukodystrophy, and PTC Therapeutics, where he managed the U.S. launch of a treatment for Duchenne muscular dystrophy. His experience also spans commercial leadership roles at Celgene and NPS Pharma (Shire).
Reflecting on his new position, Parker stated, “I am pleased to join Savara and work with a group of talented leaders who are deeply committed to developing and delivering transformative therapeutics for patients suffering from rare disease. I believe molgramostim, if approved, is uniquely positioned to make a significant impact in the treatment of aPAP, and it is a privilege to be able to bring my experience and knowledge to Savara to support a product with such great potential.”
Savara plans to submit a Biologics License Application for molgramostim to the U.S. FDA in the first half of 2025. The drug has received several designations from regulatory bodies, including Orphan Drug and Breakthrough Therapy status from the FDA, underscoring its potential impact on the treatment landscape for aPAP.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.